The European Commission opens proceedings

	Release date: 07-01-2010
	Release time: 12:08

Today, the European Commission has notified Lundbeck that it has opened proceedings against Lundbeck. The purpose is to identify whether Lundbeck has misused a dominant position or has been involved in anticompetitive agreements in the markets for citalopram.

Lundbeck is cooperating fully with the European Commission. Lundbeck is confident that the Group has complied with all relevant national and EU competition legislation.

Financial guidance

The content of this release will have no influence on the Lundbeck Group's financial result for 2009.

Â

Lundbeck contacts

Investors:	Media:
Â	Â
Jacob Tolstrup	Mads Kronborg
Director, IR & Communication	Media Relations
+45 36 43 30 79	+45 36 43 28 51
Â	Â
Palle Holm Olesen	Â
Head of Investor Relations	Â
+45 36 43 24 26	Â
Â	Â
Magnus Thorstholm Jensen	Â
Investor Relations Officer	Â
+45 36 43 38 16	Â

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, HuntingtonÂ’s, AlzheimerÂ’s and ParkinsonÂ’s diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the worldÂ’s leading pharmaceutical companies working with CNS disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit www.lundbeck.com.

The European Commission opens proceedings

Â

Lundbeck contacts

Read also